ACADEMIA
Development of AT2 Receptor-Related New Drugs Forging Ahead Overseas, but Japan Is “Far Behind”
The protective arms of the renin-angiotensin system (RAS), which have organ-protective functions, have received considerable attention primarily in Europe and the US, and R&D activity is flourishing. In particular, the angiotensin II type 2 (AT2) receptor is believed to have…
To read the full story
ACADEMIA
- Tavneos Data Integrity Issue Could Spill Over to Japan, Investigator Warns
June 2, 2026
- Arava Safety Backup at Risk as Questran Supply Falters on Nitrosamine Issue
May 11, 2026
- NCC Launches First Japan Trial for CP Inhibitor-Related Liver Dysfunction
April 27, 2026
- Dementia Drugs See Modest Uptake in Japan amid Eligibility Limits, Safety Concerns
April 9, 2026
- Cancer Drug Supply Risks Spur Calls for Pricing Reform: JSMO
March 31, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





